Trial Profile
Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec/insulin aspart (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 20 Nov 2021 Results assessing long-term safety outcomes over 1 year among patients with diabetes mellitus initiated on IDegAsp in clinical practice; long-term clinical outcomes associated with the use of IDegAsp were assessed as a secondary outcome, published in the Advances in Therapy.
- 26 Nov 2018 Status changed from active, no longer recruiting to completed.
- 03 Aug 2018 Status changed from recruiting to active, no longer recruiting.